Product Description
HRS-7058 is a novel, highly effective, and selective drug intended to treat advanced solid tumors with KRASG12C mutations. (Sourced from: https://www.moomoo.com/news/post/34522732/hengrui-pharmaceutical-600276-sh-subsidiary-hrs-7058-tablets-and-hrs?level=1&data_ticket=1712673182144017)
Mechanisms of Action: KRAS G12C Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shandong Shengdi Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for HRS-7058](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HRS-7058-101 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2026-06-01 |